Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
5(50%)
Results Posted
67%(2 trials)

Phase Distribution

Ph not_applicable
5
50%
Ph phase_1
1
10%
Ph phase_2
3
30%

Phase Distribution

1

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
1(11.1%)
Phase 2Efficacy & side effects
3(33.3%)
N/ANon-phased studies
5(55.6%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

5

trials recruiting

Total Trials

10

all time

Status Distribution
Active(6)
Completed(3)
Terminated(1)

Detailed Status

Completed3
Recruiting3
Active, not recruiting2
Not yet recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
5
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (11.1%)
Phase 23 (33.3%)
N/A5 (55.6%)

Trials by Status

active_not_recruiting220%
completed330%
not_yet_recruiting110%
withdrawn110%
recruiting330%

Recent Activity

5 active trials
Showing 5 of 10
active_not_recruitingphase_1

Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer

NCT02595879
recruitingphase_2

Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda

NCT07276360
not_yet_recruitingnot_applicable

Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer

NCT07468903
completednot_applicable

Hyperthermia and High Dose Rate Radiation Therapy in Treating Patients With Recurrent Prostate Cancer After Radiation

NCT02899221
recruitingnot_applicable

Proton Radiation Therapy for the Treatment of Patients With High Risk Prostate Cancer

NCT04725903
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT02595879Phase 1

Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer

Active Not Recruiting
NCT07276360Phase 2

Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda

Recruiting
NCT07468903Not Applicable

Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer

Not Yet Recruiting
NCT02899221Not Applicable

Hyperthermia and High Dose Rate Radiation Therapy in Treating Patients With Recurrent Prostate Cancer After Radiation

Completed
NCT04725903Not Applicable

Proton Radiation Therapy for the Treatment of Patients With High Risk Prostate Cancer

Recruiting
NCT04253483Phase 2

Comparison of High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy for the Treatment of Localized Prostate Cancer

Active Not Recruiting
NCT04945642Not Applicable

High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma

Recruiting
NCT02526498Phase 2

Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery

Completed
NCT04399824Not Applicable

Focal Radiation Therapy for the Treatment of Low or Intermediate-Risk Prostate Cancer

Withdrawn
NCT03162523

Experiences With HDR-brachytherapy in Norway

Completed

All 10 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
10